Trending NewsTrending NewsNYSE:JNJ Johnson & Johnson (JNJ) Stock Price, News & Analysis $253.68 -0.23 (-0.09%) Closing price 10/15/2026 03:59 PM EasternExtended Trading$253.64 -0.05 (-0.02%) As of 07:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Johnson & Johnson Stock (NYSE:JNJ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Johnson & Johnson alerts:Sign Up Key Stats Today's Range$252.62▼$262.4550-Day Range$248.90▼$278.6652-Week Range$184.66▼$281.07Volume9.27 million shsAverage Volume7.69 million shsMarket Capitalization$611.35 billionP/E Ratio38.44Dividend Yield2.11%Price Target$274.35Consensus RatingModerate Buy Company Overview Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world. The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension. The MedTech segment develops technologies and products used in surgery, orthopaedics, cardiovascular care, vision care and other medical specialties. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson has a long history in healthcare and formerly operated a substantial consumer health business. That consumer health business was separated into Kenvue in 2023, allowing Johnson & Johnson to focus primarily on pharmaceutical and medical technology operations. The company is led by Chairman and Chief Executive Officer Joaquin Duato.AI Generated. May Contain Errors. Read More Johnson & Johnson Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreJNJ MarketRank™: 4.07120336311 of 5 starsJohnson & Johnson scored higher than 81% of companies evaluated by MarketBeat, and ranked 81st out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingModerate Buy Consensus RatingJohnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 18 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Johnson & Johnson is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageJohnson & Johnson has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Johnson & Johnson's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth7.84% Earnings GrowthEarnings for Johnson & Johnson are expected to grow by 7.84% in the coming year, from $11.10 to $11.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Johnson & Johnson is 38.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 36.34.Price to Earnings Ratio vs. SectorThe P/E ratio of Johnson & Johnson is 38.44, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 213.39.Price to Earnings Growth RatioJohnson & Johnson has a PEG Ratio of 2.59. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJohnson & Johnson has a P/B Ratio of 7.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.92% of the float of Johnson & Johnson has been sold short.Short Interest Ratio / Days to CoverJohnson & Johnson has a short interest ratio ("days to cover") of 3.27, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Johnson & Johnson has recently increased by 4.16%, indicating that investor sentiment is decreasing. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldJohnson & Johnson pays a meaningful dividend of 2.16%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthJohnson & Johnson has been increasing its dividend for 64 years.Dividend CoverageThe dividend payout ratio of Johnson & Johnson is 81.21%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 44.78% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.Read more about Johnson & Johnson's dividend. News and Social Media2.8 / 5News Sentiment0.53 News SentimentJohnson & Johnson has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 129 news articles for Johnson & Johnson this week, compared to 9 articles on an average week.Search InterestOnly 90 people have searched for JNJ on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows69 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,064,544.00 in company stock.Percentage Held by Insiders0.16% of the stock of Johnson & Johnson is held by insiders.Percentage Held by Institutions69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Johnson & Johnson's insider trading history. Receive JNJ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JNJ Stock News HeadlinesJohnson & Johnson Q3 sets negative tone for broader pharma sector: Analysts15 minutes ago | msn.comJohnson & Johnson (JNJ) Sees $107.4 Million in Net ETF Buying on Wednesday15 minutes ago | finance.yahoo.comThis Tiny Sub-$1 Gold-Silver Royalty Stock Is Ready to RunA gold-silver royalty firm just closed the largest transaction in its history a new gold streaming deal on a producing mine. The company earns cash flow without operating a single mine, and shares still trade below $1. A major mining financier has already invested and joins the CEO in an exclusive interview.October 16 at 1:00 AM | Digest Publishing (Ad)Does Raised 2026 Outlook Change The Bull Case For Johnson & Johnson (JNJ)?15 minutes ago | finance.yahoo.comSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJohnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook.October 13 at 4:20 PM | marketbeat.com3 Healthcare Dividend Stocks Offering More Than Just IncomeAbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.September 30, 2026 | marketbeat.comThe September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks (JNJ)As Fed and inflation worries mount, Casey's General Stores, Johnson & Johnson, and PepsiCo stand out as defensive dividend payers with healthy balance sheets, growing payouts, and buyback programs.September 17, 2026 | marketbeat.comThe September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks (JNJ)As Fed and inflation worries mount, Casey's General Stores, Johnson & Johnson, and PepsiCo stand out as defensive dividend payers with healthy balance sheets, growing payouts, and buyback programs.September 17, 2026 | marketbeat.comSee More Headlines JNJ Stock Analysis - Frequently Asked Questions How have JNJ shares performed this year? Johnson & Johnson's stock was trading at $207.07 on January 1st, 2026. Since then, JNJ stock has increased by 22.5% and is now trading at $253.6840. How were Johnson & Johnson's earnings last quarter? Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings results on Tuesday, October, 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm's revenue for the quarter was up 5.9% on a year-over-year basis. Read the conference call transcript. Does Johnson & Johnson have any subsidiaries? Johnson & Johnson subsidiaries include these companies: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and others. Who are Johnson & Johnson's major shareholders? Johnson & Johnson's top institutional investors include Ninety One UK Ltd (0.27%), Assenagon Asset Management S.A. (0.12%), Mn Services Vermogensbeheer B.V. (0.03%) and Hamlin Capital Management LLC (0.03%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Kathryn E Wengel, Timothy Schmid, Vanessa Broadhurst, Robert J Decker, Elizabeth Forminard and Mark A Weinberger. View institutional ownership trends. How do I buy shares of Johnson & Johnson? Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Johnson & Johnson own? Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include NVIDIA (NVDA), Pfizer (PFE), JPMorgan Chase & Co. (JPM), AbbVie (ABBV), Walmart (WMT), Procter & Gamble (PG) and AT&T (T). Company Calendar Record date for 9/8 Dividend8/25/2026Ex-Dividend for 9/8 Dividend8/25/2026Dividend Payable9/08/2026Last Earnings10/13/2026Today10/15/2026Record date for 12/8 Dividend11/24/2026Ex-Dividend for 12/8 Dividend11/24/2026Dividend Payable12/08/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 3 days ago, JNJ's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:JNJ CIK200406 Webwww.jnj.com Phone(732) 524-0400Fax732-214-0332Employees138,200Year Founded1886Price Target and Rating Average Price Target for Johnson & Johnson$274.35 High Price Target$320.00 Low Price Target$210.00 Potential Upside/Downside+8.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)$6.60 Trailing P/E Ratio38.44 Forward P/E Ratio22.85 P/E Growth2.59Net Income$26.80 billion Net Margins16.20% Pretax Margin17.86% Return on Equity31.54% Return on Assets13.00% Debt Debt-to-Equity Ratio0.44 Current Ratio1.09 Quick Ratio0.81 Sales & Book Value Annual Sales$99.34 billion Price / Sales6.15 Cash Flow$14.11 per share Price / Cash Flow17.98 Book Value$33.85 per share Price / Book7.49Miscellaneous Outstanding Shares2,409,898,000Free Float2,406,042,000Market Cap$611.35 billion OptionableOptionable Beta0.21 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:JNJ) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersMelting The GodsChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredStop picking AI winners. Start collecting every ThursdayOne fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution ...Investors Alley | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Johnson & Johnson Please log in to your account or sign up in order to add this asset to your watchlist. Share Johnson & Johnson With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
